Inclusion Criteria:  Histologically confirmed endometrial adenocarcinoma  Patient is a candidate for adjuvant pelvic radiation (+/- vault brachytherapy), meeting one of the following conditions:  Patient has serous, clear cell, carcinosarcoma or differentiated histologies. Outer-half myometrial invasion and FIGO grade 1-2 OR FIGO stage II - IIIC1. Willing and able to give informed consent to participate in this clinical trial. Age ≥18 years. Are to receive adjuvant systemic therapy in addition to pelvic radiotherapy will be eligible provided that there is at minimum a 3-week interval between any radiation treatment and chemotherapy treatments. Willing and able to complete the QLQ-C30 questionnaire with EN-24 companion as described in the study protocol. Primary language of the patient must be English or, if a patient's primary language is not English, they are still able to participate provided the QLQ-C30 and EN-24 is available in their primary language.  Exclusion Criteria:  Has had prior pelvic radiotherapy. Has a contraindication to pelvic radiotherapy, such as but not limited to a connective tissue disease or inflammatory bowel disease. Has a contraindication to iodinated CT contrast. Has a hip prosthesis.